CP
IMCR icon

Caligan Partners’s Immunocore IMCR Stock Holding History

Caligan Partners’s Portfolio IMCR Stock Details IMCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$43.9M Buy
+1,381,317
New +$40.9M 2.06% 12

Other funds holding IMCR

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Caligan Partners's IMCR Position: Q2 2026 in Review

Caligan Partners opened a new position in Immunocore (IMCR) in Q2 2026: 1,381,317 shares worth $43.9M. The stake represents 2.06% of the portfolio and ranks #12 among its holdings.

119 funds tracked by Wall St. Rank hold IMCR as of Q2 2026.

  • Caligan Partners held 1,381,317 shares of Immunocore worth $43.9M as of Q2 2026.
  • Immunocore was a new Caligan Partners position in Q2 2026.
  • Immunocore made up 2.06% of Caligan Partners's portfolio in Q2 2026, its #12 holding.
  • 119 funds tracked by Wall St. Rank held Immunocore as of Q2 2026.

Based on Caligan Partners's 13F filing for Q2 2026, filed 14 Aug 2026.